Peregrine Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Peregrine Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Peregrine Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Peregrine Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Peregrine Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Peregrine Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Peregrine Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Peregrine Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

- Evaluate Peregrine Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Peregrine Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Peregrine Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Peregrine Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Peregrine Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Peregrine Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Peregrine Pharmaceuticals, Inc. Snapshot 5
Peregrine Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Peregrine Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Peregrine Pharmaceuticals, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Peregrine Pharmaceuticals, Inc. - Pipeline Products Glance 15
Peregrine Pharmaceuticals, Inc. - Late Stage Pipeline Products 15
Phase III Products/Combination Treatment Modalities 15
Peregrine Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Peregrine Pharmaceuticals, Inc. - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Peregrine Pharmaceuticals, Inc. - Drug Profiles 20
bavituximab 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Cotara 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
PGN-632 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Peregrine Pharmaceuticals, Inc. - Pipeline Analysis 28
Peregrine Pharmaceuticals, Inc. - Pipeline Products by Target 28
Peregrine Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 29
Peregrine Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 30
Peregrine Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 31
Peregrine Pharmaceuticals, Inc. - Recent Pipeline Updates 32
Peregrine Pharmaceuticals, Inc. - Dormant Projects 40
Peregrine Pharmaceuticals, Inc. - Discontinued Pipeline Products 41
Discontinued Pipeline Product Profiles 41
bavituximab 41
Peregrine Pharmaceuticals, Inc. - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44

List of Tables
Peregrine Pharmaceuticals, Inc., Key Information 5
Peregrine Pharmaceuticals, Inc., Key Facts 5
Peregrine Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8
Peregrine Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9
Peregrine Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10
Peregrine Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 11
Peregrine Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12
Peregrine Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014 13
Peregrine Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 14
Peregrine Pharmaceuticals, Inc. - Phase III, 2014 15
Peregrine Pharmaceuticals, Inc. - Phase II, 2014 16
Peregrine Pharmaceuticals, Inc. - Phase I, 2014 17
Peregrine Pharmaceuticals, Inc. - Preclinical, 2014 18
Peregrine Pharmaceuticals, Inc. - Discovery, 2014 19
Peregrine Pharmaceuticals, Inc. - Pipeline by Target, 2014 28
Peregrine Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 29
Peregrine Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 30
Peregrine Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 31
Peregrine Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 32
Peregrine Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 40
Peregrine Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 41
Peregrine Pharmaceuticals, Inc., Subsidiaries 42